Non-Malignant Hematologic Disorders
Conditions
Keywords
T-cell, B-cell, CliniMACS System, Melphalan, Thiotepa, Clofarabine, Fludarabine, 17-596
Brief summary
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.
Interventions
DRUGMelphalan
Melphalan 70 mg/m2/day x 2
DRUGThiotepa
Thiotepa 7.5 mg/kg/day x 2
DRUGClofarabine
Clofarabine 20-30 mg/m2/day x 5
DRUGFludarabine
Fludarabine 30 mg/m2/day x 5
DRUGAnti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
PROCEDURECliniMACS reagents
Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.
Eligibility
Sex/Gender
ALL
Age
1 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
Subject Inclusion Criteria: * Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is indicated including: * Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least one of the following criteria (Walters et al): 1. Cerebrovascular accident lasting longer than 24 hours 2. Impaired neuropsychological function with abnormal brain MRI/MRA 3. Recurrent hospitalizations (\>2 episodes/year over several years) or exchange transfusions for acute chest syndrome 4. Recurrent priapism 5. Stage I or II sickle chronic lung disease 6. Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration rate 30-50% of predicted normal value for age) 7. Bilateral proliferative retinopathy with major visual impairment in at least one eye 8. Osteonecrosis of multiple joints 9. Red cell alloimmunization during chronic transfusion therapy * Thalassemia major with at least one of the following criteria: 1. Age \<16 years 2. Available HLA-identical sibling 3. Red blood cell transfusion dependency 4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy) 5. Recurrence of disease after previous stem cell transplant * Bone Marrow Failure Syndromes: 1. Aplastic anemia refractory to immunosuppressive therapy 2. Diamond Blackfan Anemia refractory to conventional therapy 3. Shwachman-Diamond Syndrome 4. Severe Congenital Neutropenia 5. Congenital Amegakaryocytic Thrombocytopenia 6. Thrombocytopenia Absent Radii syndrome 7. Other marrow failure disorders not otherwise specified * Autoimmune cytopenias refractory to all conventional treatments 1. Autoimmune hemolytic anemia 2. Immune thrombocytopenia 3. Evan's syndrome 4. Pure red cell aplasia * Histiocytic disorders: 1. Hemophagocytic lymphohistiocytosis 2. High risk, recurrent or refractory Langerhans cell histiocytosis 3. Secondary HLH Subject Inclusion Criteria: * Recipient's age birth to \< 70 years old * Patients must have adequate organ function measured by: * Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must improve with exercise. * Hepatic: \< 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant for. Patients with higher bilirubin levels due to causes other than active liver disease are also eligible with PI approval e.g. patients with PNH, Gilberts disease or other hemolytic disorders. * Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for hemoglobin). * Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the normal range, then CrCl \> 70 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) \>30% of predicted normal for age. * Normal GFR in Children and Young Adults. Donor Inclusion Criteria: * Each donor must meet criteria outlined by institutional guidelines and be medically eligible to donate according to NMDP (or equivalent donor search organization) criteria including testing for antibodies to Human TLymphotrophic Virus Types I & II (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and Zika. * Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter. * Donor should be healthy and agree to receive G-CSF followed by donation of peripheral blood stem cells. * Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC collection). * Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A, B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched. Subject
Exclusion criteria
* Female patients who are pregnant or breast-feeding * Active viral, bacterial or fungal infection * Patient seropositive for HIV-I/II; HTLV-I/II * Karnofsky (adult)/Lansky (pediatric) \< 70% * Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are presently undergoing transplantation based on a multi-center protocol * Patients with Thalassemia major with Pesaro risk score \>II * Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII), α-Mannosidosis, X- ALD, Osteopetrosis Donor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 2 years | Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Melphalan/Thiotepa/Clofarabine Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan: Melphalan 70 mg/m2/day x 2
Thiotepa: Thiotepa 7.5 mg/kg/day x 2
Clofarabine: Clofarabine 20-30 mg/m2/day x 5
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS. | 1 |
| Melphalan/Thiotepa/ Fludarabine Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan: Melphalan 70 mg/m2/day x 2
Thiotepa: Thiotepa 7.5 mg/kg/day x 2
Fludarabine: Fludarabine 30 mg/m2/day x 5
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®): antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
CliniMACS reagents: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS. | 0 |
| Total | 1 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Participant no longer eligible for this protocol | 1 | 0 |
Baseline characteristics
| Characteristic | Melphalan/Thiotepa/Clofarabine | Total |
|---|---|---|
| Age, Continuous | 20 years | 20 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 1 Participants |
| Region of Enrollment United States | 1 Participants | 1 Participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 1 | 0 / 0 |
| other Total, other adverse events | 0 / 1 | 0 / 0 |
| serious Total, serious adverse events | 1 / 1 | 0 / 0 |
Outcome results
Primary
Overall Survival (OS)
Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.
Time frame: 2 years
Population: Data were not collected